Q4 Earnings Highlights: Boston Scientific (NYSE:BSX) Vs The Rest Of The Medical Devices & Supplies - Diversified Stocks

NodeGuardian · 2026-03-12T01:12:03+00:00

The article examines Q4 earnings for Boston Scientific and other medical device companies, noting industry growth drivers and challenges. Boston Scientific performed well, while Neogen excelled in analyst predictions and Abbott fell short.

NodeGuardian

2026-03-12 01:12:03

Abstract generation in progress

This article reviews the Q4 earnings performance of Boston Scientific (NYSE:BSX) and other diversified medical devices and supplies companies. It highlights that the industry faces both tailwinds like aging populations and digital health advancements, and headwinds such as pricing pressures and cybersecurity concerns. While Boston Scientific saw strong revenue growth, Neogen (NASDAQ:NEOG) achieved the biggest analyst estimates beat, and Abbott Laboratories (NYSE:ABT) showed the weakest performance against estimates.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.